Omeros Corporation (NASDAQ:OMER – Get Free Report) CAO David Borges sold 5,000 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $16.95, for a total transaction of $84,750.00. Following the transaction, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at approximately $84,750. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Omeros Stock Performance
Omeros stock opened at $17.36 on Tuesday. Omeros Corporation has a one year low of $3.94 and a one year high of $18.14. The company has a 50-day simple moving average of $11.04 and a 200-day simple moving average of $11.58. The firm has a market capitalization of $1.26 billion, a P/E ratio of 13.56 and a beta of 2.54.
Omeros (NASDAQ:OMER – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. As a group, sell-side analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several equities analysts have recently issued reports on the company. Wall Street Zen upgraded Omeros from a “hold” rating to a “buy” rating in a research report on Saturday. D. Boral Capital restated a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating on shares of Omeros in a research report on Monday, July 27th. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Weiss Ratings raised Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $38.00.
Omeros Company Profile
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
See Also
- Five stocks we like better than Omeros
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
